The combination of anti-PD-1 or anti-PD-L1 therapy with other therapeutic modalities may be the main option to achieve this, where the combination of VEGFR or mTOR inhibitors with ICI and geotechnically improves the prognosis of patients with renal cell carcinoma. Here, MTOR is linked to renal cell carcinoma.